메뉴 건너뛰기




Volumn 121, Issue 2, 2010, Pages 273-279

Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: A systematic review

Author keywords

Aromatase inhibitor; Breast cancer; Conflict of interest; Economic analysis

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN;

EID: 77953024444     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0870-7     Document Type: Review
Times cited : (27)

References (46)
  • 1
    • 0034669484 scopus 로고    scopus 로고
    • Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
    • Arimidex Study Group.
    • Nabholtz JM, Buzdar A, Pollak M et al (2000) Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18: 3758-3767
    • (2000) J Clin Oncol , vol.18 , pp. 37583767
    • Nabholtz, J.M.1    Buzdar, A.2    Pollak, M.3
  • 2
    • 0343584508 scopus 로고    scopus 로고
    • Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
    • Mouridsen H, Gershanovich M, Sun Y et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596-2606
    • (2001) J Clin Oncol , vol.19 , pp. 2596-2606
    • Mouridsen, H.1    Gershanovich, M.2    Sun, Y.3
  • 3
    • 0034128928 scopus 로고    scopus 로고
    • Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double blind trial
    • The Exemestane Study Group.
    • Kaufmann M, Bajetta E, Dirix LY et al (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double blind trial. The Exemestane Study Group. J Clin Oncol 18: 1399-1411
    • (2000) J Clin Oncol , vol.18 , pp. 1399-1411
    • Kaufmann, M.1    Bajetta, E.2    Dirix, L.Y.3
  • 4
    • 0031054095 scopus 로고    scopus 로고
    • A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with MA in postmenopausal women with advanced breast carcinoma
    • Budzar AU, Jones SE, Vogel CL et al (1997) A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with MA in postmenopausal women with advanced breast carcinoma. Cancer 79: 730-739
    • (1997) Cancer , vol.79 , pp. 730-739
    • Budzar, A.U.1    Jones, S.E.2    Vogel, C.L.3
  • 5
    • 0031943424 scopus 로고    scopus 로고
    • Letrozole, a new aromatase inhibitor for advanced breast cancer double blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
    • Dombernowsky P, Smith I, Falkson G et al (1998) Letrozole, a new aromatase inhibitor for advanced breast cancer: double blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453-461
    • (1998) J Clin Oncol , vol.16 , pp. 453-461
    • Dombernowsky, P.1    Smith, I.2    Falkson, G.3
  • 6
    • 0142181118 scopus 로고    scopus 로고
    • Anastrozole Alone or in Combination with Tamoxifen versus Tamoxifen Alone for Adjuvant Treatment of Postmenopausal Women with Early-Stage Breast Cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) Trial Efficacy and Safety Update Analyses
    • DOI 10.1002/cncr.11745
    • Baum M, Buzdar A, Cuzick J et al (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination.) trial efficacy and safety update analyses. Cancer 98: 1802-1810 (Pubitemid 37310221)
    • (2003) Cancer , vol.98 , Issue.9 , pp. 1802-1810
    • Baum, M.1    Buzdar, A.2    Cuzick, J.3    Forbes, J.4    Houghton, J.5    Howell, A.6    Sahmoud, T.7
  • 9
    • 34249936011 scopus 로고    scopus 로고
    • Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor
    • Goss PE, Ingle JN, Martino S et al (2007) Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor. J Clin Oncol 25: 2006-2011
    • (2007) J Clin Oncol , vol.25 , pp. 2006-2011
    • Goss, P.E.1    Ingle, J.N.2    Martino, S.3
  • 10
    • 77953022009 scopus 로고    scopus 로고
    • The role of aromatase inhibitors in adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Guideline recommendations
    • Accessed 13 Oct 2009
    • Eisen A, Trudeau M, Shelly W et al. (2009) The role of aromatase inhibitors in adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: guideline recommendations. Cancer Care Ont. http://www.cancercare.on.ca/pdf/ pebc1-18f.pdf. Accessed 13 Oct 2009
    • (2009) Cancer Care Ont.
    • Eisen, A.1    Trudeau, M.2    Shelly, W.3
  • 11
    • 42449092417 scopus 로고    scopus 로고
    • Methodological issues in evaluating cost effectiveness of adjuvant aromatase inhibitors in early breast cancer: A need for improved modeling to aid decision making
    • Annemans L (2008) Methodological issues in evaluating cost effectiveness of adjuvant aromatase inhibitors in early breast cancer: a need for improved modeling to aid decision making. Pharmacoeconomics 26: 409-423
    • (2008) Pharmacoeconomics , vol.26 , pp. 409-423
    • Annemans, L.1
  • 12
    • 70349914121 scopus 로고    scopus 로고
    • Using effectiveness and cost-effectiveness to make drug coverage decisions: A comparison of Britain Australia, and Canada
    • Clement FM, Harris A, Li JJ et al (2009) Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 302: 1437-1443
    • (2009) JAMA , vol.302 , pp. 1437-1443
    • Clement, F.M.1    Harris, A.2    Li, J.J.3
  • 14
    • 0032696499 scopus 로고    scopus 로고
    • Conflict of interest and cost-effectiveness analysis
    • Krimsky S (1999) Conflict of interest and cost-effectiveness analysis. JAMA 282: 1474-1475
    • (1999) JAMA , vol.282 , pp. 1474-1475
    • Krimsky, S.1
  • 15
    • 68949135797 scopus 로고    scopus 로고
    • Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer
    • Thomas RK, Williams M, Glen J et al (2009) Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer. Breast Cancer Res Treat 117(2): 289-295
    • (2009) Breast Cancer Res Treat , vol.117 , Issue.2 , pp. 289-295
    • Thomas, R.K.1    Williams, M.2    Glen, J.3
  • 16
    • 35748962941 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: A US healthcare system perspective the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial
    • Locker GY, Mansel R, Cella D et al (2007) Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat 106(2): 229-238
    • (2007) Breast Cancer Res Treat , vol.106 , Issue.2 , pp. 229-238
    • Locker, G.Y.1    Mansel, R.2    Cella, D.3
  • 17
    • 34447326488 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial
    • DOI 10.1038/sj.bjc.6603804, PII 6603804
    • Mansel R, Locker G, Fallowfield L et al (2007) Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial. Br J Cancer 97: 152-161 (Pubitemid 47057463)
    • (2007) British Journal of Cancer , vol.97 , Issue.2 , pp. 152-161
    • Mansel, R.1    Locker, G.2    Fallowfield, L.3    Benedict, A.4    Jones, D.5
  • 18
    • 33747339240 scopus 로고    scopus 로고
    • Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis
    • Rocchi A, Verma S (2006) Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. Support Care Cancer 14: 917-927
    • (2006) Support Care Cancer , vol.14 , pp. 917-927
    • Rocchi, A.1    Verma, S.2
  • 19
    • 33947539714 scopus 로고    scopus 로고
    • Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden
    • DOI 10.1007/s10549-006-9333-6
    • Lundkvist J, Wilking N, Holmberg S et al (2007) Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. Breast Cancer Res Treat 102: 289-299 (Pubitemid 46474838)
    • (2007) Breast Cancer Research and Treatment , vol.102 , Issue.3 , pp. 289-299
    • Lundkvist, J.1    Wilking, N.2    Holmberg, S.3    Jonsson, L.4
  • 20
    • 34547102735 scopus 로고    scopus 로고
    • Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer
    • DOI 10.1002/cncr.22824
    • Risebrough NA, Verma S, Trudeau M et al (2007) Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer. Cancer 110: 499-508 (Pubitemid 47106137)
    • (2007) Cancer , vol.110 , Issue.3 , pp. 499-508
    • Risebrough, N.A.1    Verma, S.2    Trudeau, M.3    Mittmann, N.4
  • 21
    • 34748852542 scopus 로고    scopus 로고
    • Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer
    • DOI 10.1111/j.1524-4733.2007.00190.x
    • Thompson D, Taylor DC, Montoya EL et al (2007) Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health 10: 367-376 (Pubitemid 47485660)
    • (2007) Value in Health , vol.10 , Issue.5 , pp. 367-376
    • Thompson, D.1    Taylor, D.C.A.2    Montoya, E.L.3    Winer, E.P.4    Jones, S.E.5    Weinstein, M.C.6
  • 22
    • 41149179166 scopus 로고    scopus 로고
    • Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective
    • DOI 10.1007/s10549-007-9607-7
    • Delea TE, El-Ouagari K, Karnon J et al (2008) Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat 108: 375-387 (Pubitemid 351431071)
    • (2008) Breast Cancer Research and Treatment , vol.108 , Issue.3 , pp. 375-387
    • Delea, T.E.1    El-Ouagari, K.2    Karnon, J.3    Sofrygin, O.4
  • 23
    • 34347396653 scopus 로고    scopus 로고
    • Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer
    • Delea TE, Karnon J, Sofrygin O et al (2007) Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clin Breast Cancer 7: 608-618 (Pubitemid 47025818)
    • (2007) Clinical Breast Cancer , vol.7 , Issue.8 , pp. 608-618
    • Delea, T.E.1    Karnon, J.2    Sofrygin, O.3    Thomas, S.K.4    Papo, N.L.5    Barghout, V.6
  • 24
    • 34250822270 scopus 로고    scopus 로고
    • Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer
    • DOI 10.1007/s10549-006-9262-4
    • El Ouagari K, Karnon J, Delea T et al (2007) Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res Treat 101: 37-49 (Pubitemid 47555323)
    • (2007) Breast Cancer Research and Treatment , vol.101 , Issue.1 , pp. 37-49
    • Ouagari, K.E.1    Karnon, J.2    Delea, T.3    Talbot, W.4    Brandman, J.5
  • 25
    • 33644868306 scopus 로고    scopus 로고
    • Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: The UK perspective
    • DOI 10.2165/00019053-200624030-00004
    • Karnon J, Delea T, Johnston SR et al (2006) Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics 24: 237-250 (Pubitemid 43374376)
    • (2006) PharmacoEconomics , vol.24 , Issue.3 , pp. 237-250
    • Karnon, J.1    Delea, T.2    Johnston, S.R.3    Smith, R.4    Brandman, J.5    Sung, J.6    Goss, P.E.7
  • 26
    • 33746007227 scopus 로고    scopus 로고
    • Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer
    • Delea TE, Karnon J, Smith RE et al (2006) Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care 12: 374-386 (Pubitemid 44063449)
    • (2006) American Journal of Managed Care , vol.12 , Issue.7 , pp. 374-386
    • Delea, T.E.1    Karnon, J.2    Smith, R.E.3    Johnston, S.R.4    Brandman, J.5    Sung, J.C.Y.6    Goss, P.E.7
  • 27
    • 42149091256 scopus 로고    scopus 로고
    • Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: The UK perspective
    • Karnon J, Delea T, Barghout V (2008) Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. Eur J Health Econ 9: 171-183
    • (2008) Eur J Health Econ , vol.9 , pp. 171-183
    • Karnon, J.1    Delea, T.2    Barghout, V.3
  • 28
    • 34247847379 scopus 로고    scopus 로고
    • Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: Upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole
    • DOI 10.1016/j.breast.2006.12.002, PII S0960977606002207
    • Skedgel C, Rayson D, Dewar R et al (2007) Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifenexemestane and extended tamoxifen-letrozole. Breast 16: 252-261 (Pubitemid 46796849)
    • (2007) Breast , vol.16 , Issue.3 , pp. 252-261
    • Skedgel, C.1    Rayson, D.2    Dewar, R.3    Younis, T.4
  • 29
    • 33747475592 scopus 로고    scopus 로고
    • Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer
    • Gil JM, Rubio-Terrés C, Del Castillo A et al (2006) Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. Clin Transi Oncol 8: 339-348
    • (2006) Clin Transi Oncol , vol.8 , pp. 339-348
    • Gil, J.M.1    Rubio-Terrés, C.2    Del Castillo, A.3
  • 30
    • 0345095475 scopus 로고    scopus 로고
    • Cost-Effectiveness of Anastrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women with Advanced Breast Cancer
    • DOI 10.1016/S0149-2918(03)80348-X
    • Simons WR, Jones D, Buzdar A (2003) Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. Clin Ther 25: 2972-2987 (Pubitemid 37510604)
    • (2003) Clinical Therapeutics , vol.25 , Issue.11 , pp. 2972-2987
    • Simons, W.R.1    Jones, D.2    Buzdar, A.3
  • 31
    • 0036206298 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: A model for Europe and Australia
    • Lindgren P, Jönsson B, Redaelli A et al (2002) Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia. Pharmacoeconomics 20: 101-108 (Pubitemid 34275759)
    • (2002) PharmacoEconomics , vol.20 , Issue.2 , pp. 101-108
    • Lindgren, P.1    Jonsson, B.2    Redaelli, A.3    Radice, D.4
  • 32
    • 0035253478 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma
    • Hillner BE, Radice D (2001) Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma. Cancer 91: 484-489
    • (2001) Cancer , vol.91 , pp. 484-489
    • Hillner, B.E.1    Radice, D.2
  • 33
    • 0038554367 scopus 로고    scopus 로고
    • A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: For advanced breast cancer in postmenopausal patients
    • DOI 10.2165/00019053-200321070-00006
    • Karnon J, Jones T (2003) A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients. Pharmacoeconomics 21: 513-525 (Pubitemid 36560700)
    • (2003) PharmacoEconomics , vol.21 , Issue.7 , pp. 513-525
    • Karnon, J.1    Jones, T.2
  • 34
    • 0345688075 scopus 로고    scopus 로고
    • A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer
    • DOI 10.1093/annonc/mdg447
    • Karnon J, Johnston SR, Jones T et al (2003) A trial-based costeffectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer. Ann Oncol 14: 1629-1633 (Pubitemid 37455811)
    • (2003) Annals of Oncology , vol.14 , Issue.11 , pp. 1629-1633
    • Karnon, J.1    Johnston, S.R.2    Jones, T.3    Glendenning, A.4
  • 35
    • 0034058430 scopus 로고    scopus 로고
    • Economic evaluation of letrozole in the treatment of advanced breast cancer in postmenopausal women in Canada
    • DOI 10.1046/j.1524-4733.2000.31004.x
    • Nuijten M, McCormick J, Waibel F et al (2000) Economic evaluation of letrozole in the treatment of advanced breast cancer in postmenopausal women in Canada. Value Health 3: 31-39 (Pubitemid 30232946)
    • (2000) Value in Health , vol.3 , Issue.1 , pp. 31-39
    • Nuijten, M.1    McCormick, J.2    Waibel, F.3    Parison, D.4
  • 36
    • 0032727949 scopus 로고    scopus 로고
    • Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK
    • DOI 10.2165/00019053-199916040-00006
    • Nuijten M, Meester L, Waibel F et al (1999) Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK. Pharmacoeconomics 16: 379-397 (Pubitemid 29496048)
    • (1999) PharmacoEconomics , vol.16 , Issue.4 , pp. 379-391
    • Nuijten, M.1    Meester, L.2    Waibel, F.3    Wait, S.4
  • 37
    • 9644256101 scopus 로고    scopus 로고
    • Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: A literature-based model analysis of costs in the Italian national health service
    • DOI 10.1016/j.clinthera.2004.09.014, PII S0149291804803011
    • Marchetti M, Caruggi M, Colombo G (2004) Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model, analysis of costs in the Italian National Health Service. Clin Ther 26: 1546-1561 (Pubitemid 39572164)
    • (2004) Clinical Therapeutics , vol.26 , Issue.9 , pp. 1546-1561
    • Marchetti, M.1    Caruggi, M.2    Colombo, G.3
  • 38
    • 0242413719 scopus 로고    scopus 로고
    • Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer
    • DOI 10.1007/s00520-003-0502-4
    • Verma S, Rocchi A (2003) Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer. Support Care Cancer 11: 728-734 (Pubitemid 37432630)
    • (2003) Supportive Care in Cancer , vol.11 , Issue.11 , pp. 728-734
    • Verma, S.1    Rocchi, A.2
  • 39
    • 0038178935 scopus 로고    scopus 로고
    • Cost utility analysis of first-line hormonal therapy in advanced breast cancer: Comparison of two aromatase inhibitors to tamoxifen
    • DOI 10.1097/00000421-200306000-00017
    • Dranitsaris G, Verma S, Trudeau M (2003) Cost utility analysis of first-line hormonal therapy in. advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. Am J Clin Oncol 26: 289-296 (Pubitemid 36712646)
    • (2003) American Journal of Clinical Oncology: Cancer Clinical Trials , vol.26 , Issue.3 , pp. 289-296
    • Dranitsaris, G.1    Verma, S.2    Trudeau, M.3
  • 40
    • 0033805663 scopus 로고    scopus 로고
    • Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: A comparison of two aromatase inhibitors to megestrol acetate
    • Dranitsaris G, Leung P, Mather J et al (2000) Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. Anticancer Drugs 11: 591-601
    • (2000) Anticancer Drugs , vol.11 , pp. 591-601
    • Dranitsaris, G.1    Leung, P.2    Mather, J.3
  • 41
    • 4444291699 scopus 로고    scopus 로고
    • Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer
    • Hillner BE (2004) Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer, Cancer 101: 1311-1322
    • (2004) Cancer , vol.101 , pp. 1311-1322
    • Hillner, B.E.1
  • 42
    • 33846475483 scopus 로고    scopus 로고
    • Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: Sequential tamoxifen-exemestane and upfront anastrozole
    • DOI 10.1007/s10549-006-9299-4
    • Skedgel C, Rayson D, Dewar R et al (2007) Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. Breast Cancer Res Treat 101: 325-333 (Pubitemid 46169887)
    • (2007) Breast Cancer Research and Treatment , vol.101 , Issue.3 , pp. 325-333
    • Skedgel, C.1    Rayson, D.2    Dewar, R.3    Younis, T.4
  • 43
    • 33847308051 scopus 로고    scopus 로고
    • Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer
    • DOI 10.1093/annonc/mdl410
    • Younis T, Rayson D, Dewar R et al (2007) Modeling for costeffective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer. Ann Oncol 18: 293-298 (Pubitemid 46323096)
    • (2007) Annals of Oncology , vol.18 , Issue.2 , pp. 293-298
    • Younis, T.1    Rayson, D.2    Dewar, R.3    Skedgel, C.4
  • 44
    • 31544458993 scopus 로고    scopus 로고
    • Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer
    • Lønning PE (2006) Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer, Ann Oncol 17: 217-225
    • (2006) Ann Oncol , vol.17 , pp. 217-225
    • Lønning, P.E.1
  • 45
    • 33747614085 scopus 로고    scopus 로고
    • Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: A Slovenian perspective
    • DOI 10.1097/01.cad.0000215057.47695.db, PII 0000181320060700000015
    • Piskur P, Sonc M, Cufer T et al (2006) Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective. Anticancer Drugs 17: 719-724 (Pubitemid 44265873)
    • (2006) Anti-Cancer Drugs , vol.17 , Issue.6 , pp. 719-724
    • Piskur, P.1    Sonc, M.2    Cufer, T.3    Borstnar, S.4    Mrhar, A.5
  • 46
    • 33748760878 scopus 로고    scopus 로고
    • Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial
    • DOI 10.1111/j.1525-1438.2006.00699.x
    • Moeremans K, Annemans L (2006) Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial. Int J Gynecol Cancer 16: 576-578 (Pubitemid 44410972)
    • (2006) International Journal of Gynecological Cancer , vol.16 , Issue.SUPPL. 2 , pp. 576-578
    • Moeremans, K.1    Annemans, L.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.